Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 6;14:3188. doi: 10.1038/s41467-023-38946-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Neoantigen- and TAA-specific CD8 T cells were purified from in vitro expanded CD8 T cells of melanoma, ovarian, lung or colorectal cancer patients and virus-specific CD8 were isolated from healthy donors and cancer patients. After single-cell cloning and expansion, individual clones were subjected to antigen sensitivity and structural avidity measurements as well as TCR sequencing. Molecular modeling of pMHC-TCR interactions were also performed. b Representative examples of structural avidity of virus-, TAA- and neoantigen-specific CD8 T cells. Structural avidity was determined with reversible pMHC multimers to measure monomeric pMHC-TCR T_1/2. c Structural avidity of individual virus-, TAA- or neoantigen-specific CD8 T cells (mean ± SEM). The number of clones is indicated in brackets (each clone was tested individually). d Cumulative structural avidities per classes of antigen- (virus, TAAs and neoantigen)-specific CD8 T cells. The number of clones is indicated in brackets. P values are provided when significant at 95% confidence interval and using two-sided Mann–Whitney test. e Coefficient of determination R² of the regression analyses (Supplementary Fig. 4a–f) between pMHC binding/stability and immunogenicity predictors values and the medians of T_1/2 (s) or EC₅₀ (M) of antigen-specific CD8 T cells. Pearson coefficients (two-sided test) were calculated and mentioned when significant. Patients and clones are described in Supplementary Tables 1 and 2. Source data are provided as a Source Data file.